These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27072578)

  • 1. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.
    Wang JH; Wang H; Wang YJ; Xia ZJ; Huang HQ; Jiang WQ; Lu Y
    Oncotarget; 2016 Jun; 7(23):35412-22. PubMed ID: 27072578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
    Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
    Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
    Wei W; Wu P; Li L; Zhang ZH
    Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial.
    Tian XP; Cai J; Xia Y; Zhang YC; Wang L; Liu PP; Huang HQ; Li YJ; Zhou H; Li ZM; Yang J; Wei LQ; Zou QH; Huang Y; Li J; Ling L; Zhong WL; Cai QQ
    Lancet Haematol; 2024 May; 11(5):e336-e344. PubMed ID: 38554717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma.
    Jing XM; Zhang ZH; Wu P; Zhang SC; Ren YR; Xiong ZJ; Wei W; Luo L; Li L
    Leuk Res; 2016 Aug; 47():26-31. PubMed ID: 27239738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.
    Wang L; Wang WD; Xia ZJ; Zhang YJ; Xiang J; Lu Y
    Med Oncol; 2014 Mar; 31(3):860. PubMed ID: 24481637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study.
    Wang H; Wuxiao ZJ; Zhu J; Wang Z; Wang KF; Li S; Chen X; Lu Y; Xia ZJ
    Leuk Lymphoma; 2015 Apr; 56(4):971-7. PubMed ID: 24991715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
    Wang L; Wang ZH; Chen XQ; Li YJ; Wang KF; Xia YF; Xia ZJ
    Cancer; 2013 Jan; 119(2):348-55. PubMed ID: 22811078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q
    Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study.
    Li JW; Li YJ; Zhong MZ; Liu XL; Li J; Li KL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Zhou H; Yi PY
    Eur J Haematol; 2018 Mar; 100(3):247-256. PubMed ID: 29194798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma.
    Feng D; Yan Z; Fu B; Bai S; Zhu L; Gale RP; Xia Z; Liang Y; Wang H
    Hematology; 2024 Dec; 29(1):2402102. PubMed ID: 39268981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
    Zhou Z; Li X; Chen C; Li X; Zhang L; Li L; Wang X; Ma W; Fu X; Wu J; Sun Z; Zhang X; Li Z; Yan J; Chang Y; Lu L; Qin B; Li X; Wen J; Zhang M
    Ann Hematol; 2014 Nov; 93(11):1889-94. PubMed ID: 24923454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
    Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
    Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.
    Zhang L; Jia S; Ma Y; Li L; Li X; Wang X; Fu X; Ma W; Qin Y; Li W; Wu J; Sun Z; Zhang X; Nan F; Chang Y; Li Z; Zhang D; Wang G; Yan J; Su L; Wang J; Xue H; Young KH; Zhang M
    Oncotarget; 2016 Aug; 7(34):55721-55731. PubMed ID: 27384676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of P-Gemox chemotherapy combined with radiotherapy in newly diagnosed,stage ⅠE to ⅡE, extranodal nasal type natural killer/T-cell lymphoma].
    Ji J; Li L; She NN; Liu XH; Long Y; Zhang XB
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Feb; 33(2):132-137. PubMed ID: 30808138
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.
    Cai J; Liu P; Huang H; Li Y; Ma S; Zhou H; Tian X; Zhang Y; Gao Y; Xia Y; Zhang X; Yang H; Li L; Cai Q
    Signal Transduct Target Ther; 2020 Dec; 5(1):289. PubMed ID: 33376237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma.
    Bi XW; Xia Y; Zhang WW; Sun P; Liu PP; Wang Y; Huang JJ; Jiang WQ; Li ZM
    Ann Hematol; 2015 Sep; 94(9):1525-33. PubMed ID: 25957850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
    Zhang L; Li S; Jia S; Nan F; Li Z; Cao J; Fan S; Zhang C; Su L; Wang J; Xue H; Zhang M
    Oncotarget; 2016 Sep; 7(36):58396-58404. PubMed ID: 27517317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma.
    Zhang J; Jiang W; Wang WD; Liu CC; Hu YP; Xia ZJ
    Asian Pac J Cancer Prev; 2015; 16(11):4515-20. PubMed ID: 26107196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of Clinical Efficacy and Influencing Factors of Gemcitabine-L-Asparaginase-Oxaliplatin Chemotherapy Scheme and Radiotherapy for Treatment of Early ENKTL Patients].
    Qiu C; Wang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1420-1425. PubMed ID: 29070118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.